Goldman Sachs Group Inc Acadia Pharmaceuticals Inc Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,758,859 shares of ACAD stock, worth $30.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,758,859

Previous 1,340,944 31.17%

Holding current value

$30.2 Million

Previous $21.8 Million 24.22%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.14 - $19.14 $6.33 Million - $8 Million	417,915 Added 31.17%	1,758,859 $27.1 Million
Q2 2024 Aug 13, 2024	BUY	$14.62 - $18.42 $8.96 Million - $11.3 Million	613,039 Added 84.22%	1,340,944 $21.8 Million
Q1 2024 May 15, 2024	SELL	$17.79 - $30.86 $1.36 Million - $2.35 Million	-76,265 Reduced 9.48%	727,905 $13.5 Million
Q4 2023 Feb 13, 2024	BUY	$20.78 - $31.77 $1.78 Million - $2.72 Million	85,545 Added 11.9%	804,170 $25.2 Million
Q3 2023 May 14, 2024	SELL	$20.84 - $33.47 $1.78 Million - $2.86 Million	-85,545 Reduced 10.64%	718,625 $15 Million
Q3 2023 Nov 14, 2023	SELL	$20.84 - $33.47 $11.6 Million - $18.6 Million	-554,799 Reduced 43.57%	718,625 $15 Million
Q2 2023 May 14, 2024	BUY	$17.8 - $25.65 $5.23 Million - $7.53 Million	293,686 Added 29.98%	1,273,424 $30.5 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $5.23 Million - $7.53 Million	293,686 Added 29.98%	1,273,424 $30.5 Million
Q1 2023 May 14, 2024	SELL	$16.32 - $20.92 $177,643 - $227,714	-10,885 Reduced 1.1%	979,738 $18.4 Million
Q1 2023 May 11, 2023	SELL	$16.32 - $20.92 $177,643 - $227,714	-10,885 Reduced 1.1%	979,738 $18.4 Million
Q4 2022 May 14, 2024	SELL	$14.2 - $18.63 $2.69 Million - $3.54 Million	-189,775 Reduced 16.08%	990,623 $15.8 Million
Q4 2022 Feb 13, 2023	SELL	$14.2 - $18.63 $2.69 Million - $3.54 Million	-189,775 Reduced 16.08%	990,623 $15.8 Million
Q3 2022 May 14, 2024	BUY	$14.11 - $18.27 $1.73 Million - $2.25 Million	122,904 Added 11.62%	1,180,398 $19.3 Million
Q3 2022 Nov 10, 2022	BUY	$14.11 - $18.27 $1.73 Million - $2.25 Million	122,904 Added 11.62%	1,180,398 $0
Q2 2022 May 14, 2024	BUY	$13.01 - $27.22 $3.3 Million - $6.9 Million	253,324 Added 31.5%	1,057,494 $14.9 Million
Q2 2022 Aug 15, 2022	SELL	$13.01 - $27.22 $609,947 - $1.28 Million	-46,883 Reduced 4.25%	1,057,494 $14.9 Million
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $1.62 Million - $2.13 Million	-77,546 Reduced 6.56%	1,104,377 $26.7 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $5.96 Million - $9.62 Million	355,077 Added 42.94%	1,181,923 $27.6 Million
Q3 2021 Nov 10, 2021	BUY	$15.78 - $24.77 $13 Million - $20.5 Million	826,846 New	826,846 $13.7 Million

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.78B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Acadia Pharmaceuticals Inc Transaction History